Cardiovascular combination therapy
1 paper5 findings
- 1 lab in 1 country
- Humans1
Outcomes
3TDP-43 pathology
downin humans1OR 0.46
1 study
TDP-43 pathology
downin humans1OR 0.46
Cardiovascular combination therapy decreases TDP-43 pathology in humans (OR=0.46; p<0.01).
“lower odds of TDP‐43 (OR=0.46;p<0.01) and hippocampal sclerosis (OR=0.27;p=0.03).”
Humansbrain
Association of combination cardiovascular therapies with cognitive decline and neuropathologies
AAIC 2025 abstract23 Dec 2025
Alzheimer's disease neuropathology
downin humans1
1 study
Alzheimer's disease neuropathology
downin humans1
Cardiovascular combination therapy decreases Alzheimer's disease neuropathology in humans (estimate=-0.22; p<0.01).
“therapies with three medication classes were associated with lower odds of atherosclerosis (OR=0.47;p<0.01) and arteriolosclerosis (OR=0.53;p=0.01), but higher odds of brain infarcts (OR=1.74;p=0.01), particularly macroinfarcts (OR=1.66;p=0.03), as well as with less global AD pathology (estimate=‐0.22; p <0.01)”
Humansbrain
Association of combination cardiovascular therapies with cognitive decline and neuropathologies
AAIC 2025 abstract23 Dec 2025
Cognitive decline
downin humans1
1 study
Cognitive decline
downin humans1
Cardiovascular combination therapy decreases cognitive decline in humans (estimate=0.02; p=0.02).
“baseline therapies with three medication classes were associated with slower decline in global cognition (estimate=0.02;p=0.02)”
Humanscompared to no medication use
Association of combination cardiovascular therapies with cognitive decline and neuropathologies
AAIC 2025 abstract23 Dec 2025
Associations
2Cerebral infarction
upin humans1OR 1.74
1 study
Cerebral infarction
upin humans1OR 1.74
Cardiovascular combination therapy raises the risk of cerebral infarction in humans (OR=1.74; p=0.01).
“higher odds of brain infarcts (OR=1.74;p=0.01), particularly macroinfarcts (OR=1.66;p=0.03)”
Humansbrain
Association of combination cardiovascular therapies with cognitive decline and neuropathologies
AAIC 2025 abstract23 Dec 2025
Atherosclerosis
downin humans1OR 0.47
1 study
Atherosclerosis
downin humans1OR 0.47
Cardiovascular combination therapy lowers the risk of atherosclerosis in humans (OR=0.47; p<0.01).
“therapies with three medication classes were associated with lower odds of atherosclerosis (OR=0.47;p<0.01)”
Humansbrain
Association of combination cardiovascular therapies with cognitive decline and neuropathologies
AAIC 2025 abstract23 Dec 2025